ARNA Stock Recent News Arena Pharmaceuticals (ARNA) 4.53 11/14/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arena Pharmaceuticals (ARNA) 4.53 $ARNA

Belviq Weekly Sales Come In Flat
Spencer Osborne - at Seeking Alpha - 1 hr 41 mins ago

ARNA: 4.53 (-0.08)

Belviq For Smoking Cessation - Sizzle Or Smolder?
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 9:24AM CST

ARNA: 4.53 (-0.08)

ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST

OREX: 5.65 (-0.21), HLF: 38.50 (+0.65), NVO: 44.13 (+0.11), VVUS: 3.25 (-0.01), AMGN: 157.68 (-3.17), GSK: 45.74 (+0.08), ARNA: 4.53 (-0.08)

Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST

ARNA: 4.53 (-0.08)

Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically,  Arena Pharmaceuticals '   Belviq and  VIVUS 's   Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.34 (-0.08), VVUS: 3.25 (-0.01), GSK: 45.74 (+0.08), ARNA: 4.53 (-0.08)

Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.25 (-0.01), AMAG: 34.00 (-0.24), ARNA: 4.53 (-0.08)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.65 (-0.21), ARNA: 4.53 (-0.08)

Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST

ARNA: 4.53 (-0.08)

Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST

ARNA: 4.53 (-0.08)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving in Outer Banks: Unique Traditions Await

Updated Category News Views 109

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Continue Reading
Navigating Roof Damage Insurance Claims: Key Insights

Updated Category News Views 141

No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...

Continue Reading
Chime Joins S&P MidCap 400 Amid Merger Jostle

Updated Category News Views 170

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Continue Reading
Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 157

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 86

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Black Bayou Kicks Off Major Gas Storage Build in Louisiana

Updated Category News Views 164

Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...

Continue Reading
Sports Clock Radio: A Game Time Enthusiast's Dream

Updated Category News Views 147

A New Gadget for the Diehard Fan Fanatics, gather 'round. There's an innovation rolling out that's looking to marry the good old alarm clock radio with the rush of game day fever! Over in Pittsburgh, an inventor's cooking up something that every loyal sports fan might soon find irresistible—a Sports Clock Radio, bringing the stadium experience to your living room or...

Continue Reading
Schools Reimagine Yearbooks with Interactive Archives

Updated Category News Views 133

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 87

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Pine AI Unveils AI Studio & Real-World Call Feature

Updated Category News Views 208

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Act in Crocs Class Action Suit - Deadline March 2025

Updated Category News Views 156

Investors Targeting Crocs Encouraged to Join Class Action Faruqi & Faruqi, LLP, a prominent name in securities litigation, is reaching out to investors who have experienced significant losses in Crocs stock to participate in an emerging federal class action lawsuit. The firm is particularly concerned with those who incurred losses exceeding $50,000. The deadline to assume...

Continue Reading
Chaoyang District: Fusion of Culture and Business

Updated Category News Views 57

Chaoyang: A Tapestry of Global Life Taking a stroll through Beijing's Chaoyang district, you'd catch more than just a glimpse of its soaring skyscrapers or riverside parks—you're stepping into a melting pot of cultures and modern business ethos. It’s not puffery when they say this district marries the world’s diversified cultures with dynamic business environments;...

Continue Reading
Foot Locker Poised for Earnings Growth with Nike Alliance

Updated Category News Views 251

Foot Locker on the Path to Recovery Recent analysis by Needham's analyst Tom Nikic illustrates a promising outlook for Foot Locker, Inc. (NYSE: FL), highlighting how the company is positioned for earnings recovery in the coming year. The strengthened partnership with Nike, along with growth in non-Nike brands, and recent investments in selling, general and administrative...

Continue Reading
Future Growth of Milking Automation Market to $3.68 Billion

Updated Category News Views 133

The Rising Trend of Milking Automation Market The milking automation market is currently experiencing a significant transformation, with estimates projecting a growth to USD 3.68 billion by 2030. This steady rise reflects a robust CAGR of 7.1% from an initial valuation of USD 2.61 billion. Factors driving this expansion include increasing demand for milk, labor shortages...

Continue Reading
Immatics Shares New Phase 1b Data for Melanoma Therapy IMA203

Updated Category News Views 110

Immatics Updates on ACTengine® IMA203 for Melanoma Patients Overview: Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies, has recently announced significant advancements in its clinical trial of ACTengine® IMA203. The focus of this update is on the therapy's application in...

Continue Reading